Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ADHD
- Previous Close: $1.25
- 50 Day Moving Average: $1.44
- 200 Day Moving Average: $2.76
- 52-Week Range: $0.83 - $5.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.16
- P/E Growth: 0.00
- Market Cap: $33.90M
- Outstanding Shares: 27,562,000
- Beta: 1.33
- Return on Equity: -38.21%
- Return on Assets: -36.62%
Companies Related to Alcobra:
- Current Ratio: 15.99%
- Quick Ratio: 15.99%
What is Alcobra's stock symbol?
Alcobra trades on the NASDAQ under the ticker symbol "ADHD."
Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?
10 equities research analysts have issued 1 year price targets for Alcobra's shares. Their forecasts range from $1.25 to $4.00. On average, they anticipate Alcobra's stock price to reach $2.16 in the next twelve months.
When will Alcobra announce their earnings?
Alcobra is scheduled to release their next quarterly earnings announcement on Wednesday, May, 17th 2017.
What are analysts saying about Alcobra stock?
Here are some recent quotes from research analysts about Alcobra stock:
According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (1/24/2017)
- Piper Jaffray Companies analysts commented, "We're not particularly surprised by this outcome as the truncated dataset greatly reduced the power of this trial to demonstrate a significant impact on the CAARS. Alcobra now plans to use its ~$50M in cash to execute on a new business plan, the details of which should become available during 1Q17. We expect this could involve development of MDX in ex-US markets, or of new candidates from the company's internal pipeline or in-licensing efforts. Given the prolonged timelines to next clinical data and first revenues, as well as increased execution risk we see for this team, we are reducing our PT from $3 to $1.50, or roughly equivalent to cash/share. In advance of more details on a plan forward, we reiterate N." (1/17/2017)
Cantor Fitzgerald analysts commented, "an opportunity to achieve a statistically significant result with substantive hanged incorporated in the ongoing Phase III trial." Despite the failure of the first Phase III study, the analyst thought MDX had a better shot this time after implementing several protocol changes. Related Link: Goldman Initiates Specialty Pharma At Neutral, Highlights "A Confluence Of Concerns"Thriving Market ConditionsAdditionally, the "large" ADHD market has been growing at healthy levels according to the Goldstein. "The market has been fueled by the growing awareness of ADHD [...] changes in diagnosing the disorder [...] and enhanced formulations of existing stimulant base drugs," said the analyst. Alcobra's MDX was expected to be a viable competitor, able to both "cannibalize share of existing drugs as well as grow the market," (6/7/2016)
Who owns Alcobra stock?
Alcobra's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (16.25%), Broadfin Capital LLC (7.46%), Alyeska Investment Group L.P. (2.96%), Kingdon Capital Management L.L.C. (2.36%), Royce & Associates LP (2.34%) and Palo Alto Investors LLC (0.99%).
Who sold Alcobra stock? Who is selling Alcobra stock?
Alcobra's stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..
Who bought Alcobra stock? Who is buying Alcobra stock?
Alcobra's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Royce & Associates LP, J. Goldman & Co LP, Kingdon Capital Management L.L.C. and Broadfin Capital LLC.
How do I buy Alcobra stock?
Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alcobra stock cost?
One share of Alcobra stock can currently be purchased for approximately $1.21.